TY - JOUR
T1 - Monoclonal gammopathies of undetermined significance
AU - Kyle, Robert A.
AU - Rajkumar, S. Vincent
N1 - Funding Information:
This was supported in part by a research grant, CA 62242, from the National Cancer Institute.
PY - 2002/9
Y1 - 2002/9
N2 - The term 'monoclonal gammopathy of undetermined significance' denotes the presence of a monoclonal protein in patients without evidence of multiple myeloma, macroglobulinemia, amyloidosis or related plasma cell proliferative disorders. The disorder has been found in approximately 3% of persons older than 70 years and in approximately 1% of persons older than 50 years. A population-based study included 1384 patients from south-eastern Minnesota who had the disorder diagnosed at the Mayo Clinic from 1960 through 1994. Risk of progression was about 1% per year, but patients were at risk of progression even after 25 years or more of stable monoclonal gammopathy of undetermined significance. The risk for development of multiple myeloma was increased 25-fold; the risk of macroglobulinemia, 46-fold; and the risk of primary amyloidosis, 8.4-fold. Concentration and type of monoclonal protein were the only independent predictors of progression. The presence of a urine monoclonal protein and the reduction of one or more uninvolved immunoglobulins were not risk factors for progression. Monoclonal gammopathy of undetermined significance may be associated with various disorders, including lymphoproliferative diseases, leukemia, von Willebrand disease, connective tissue diseases and neurologic disorders.
AB - The term 'monoclonal gammopathy of undetermined significance' denotes the presence of a monoclonal protein in patients without evidence of multiple myeloma, macroglobulinemia, amyloidosis or related plasma cell proliferative disorders. The disorder has been found in approximately 3% of persons older than 70 years and in approximately 1% of persons older than 50 years. A population-based study included 1384 patients from south-eastern Minnesota who had the disorder diagnosed at the Mayo Clinic from 1960 through 1994. Risk of progression was about 1% per year, but patients were at risk of progression even after 25 years or more of stable monoclonal gammopathy of undetermined significance. The risk for development of multiple myeloma was increased 25-fold; the risk of macroglobulinemia, 46-fold; and the risk of primary amyloidosis, 8.4-fold. Concentration and type of monoclonal protein were the only independent predictors of progression. The presence of a urine monoclonal protein and the reduction of one or more uninvolved immunoglobulins were not risk factors for progression. Monoclonal gammopathy of undetermined significance may be associated with various disorders, including lymphoproliferative diseases, leukemia, von Willebrand disease, connective tissue diseases and neurologic disorders.
UR - http://www.scopus.com/inward/record.url?scp=0036760289&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036760289&partnerID=8YFLogxK
U2 - 10.1046/j.1468-0734.2002.00076.x
DO - 10.1046/j.1468-0734.2002.00076.x
M3 - Review article
C2 - 12616697
AN - SCOPUS:0036760289
SN - 1127-0020
VL - 6
SP - 225
EP - 252
JO - Reviews in Clinical and Experimental Hematology
JF - Reviews in Clinical and Experimental Hematology
IS - 3
ER -